Talazoparib plus hormone therapy for metastatic prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether talazoparib added to standard hormone therapy (ADT), along with abiraterone, can better control metastatic prostate cancer that hasn’t progressed despite starting hormone treatment. It may help people live longer and delay cancer worsening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer confirmed by biopsy or cell testing (adenocarcinoma).
- Your cancer has spread (metastatic disease) to soft tissue and/or bone before starting hormone therapy.
- You can have had some hormone treatment already, but the timing must fit the study rules (no more than 60 days for new starts; specific limits if you had earlier treatment).
- Your health and blood counts must be adequate (Karnofsky 60–100, and lab values like blood counts, kidney function, and liver enzymes within set limits).
- You must have recent scans done near the start of hormone therapy so the team can document what’s there.
- You cannot have certain prior treatments or conditions, like prior chemotherapy for metastatic prostate cancer, brain metastases, and major uncontrolled heart or blood pressure problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for men with advanced prostate cancer that has stopped responding to usual hormone therapy. It compares high-dose testosterone followed by darolutamide to standard care, and may help control the cancer longer.
This Phase 2 trial tests whether adding niraparib to standard hormone therapy (androgen ablation) after radiation works better for men with high-risk, localized or locally advanced prostate cancer. It may help control the cancer for longer, while also collecting extra tissue and blood to study why the treatment works or doesn’t.
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
This trial tests a combination of two drugs, talazoparib and enzalutamide, in men with advanced prostate cancer that has progressed after previous treatment with a hormone therapy called an AR inhibitor. It aims to see if this combination can help control the cancer and delay further progression.
This expanded access program provides the experimental drug talazoparib (given in combination with enzalutamide) to patients with newly diagnosed metastatic prostate cancer that has become castrate-resistant (no longer responding to hormone therapy). The goal is to make this treatment available before it is formally approved.
This trial studies whether taking talazoparib and enzalutamide before surgery can shrink or control prostate cancer. If treatment works, it may make the cancer easier to remove with a radical prostatectomy.
Hear when a new Castration-Sensitive Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.